Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Сравнительная оценка эффективности фотемустина и дакарбазина у больных диссеминированной меланомой. Клиническое исследование III фазы
M.F. Avril, S. Aamdal, J.J. Grob et al. Сравнительная оценка эффективности фотемустина и дакарбазина у больных диссеминированной меланомой. Клиническое исследование III фазы. Онкология. 2006; 1: 80-82.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Balch CM, Reintgen DS, Kirkwood JM. Cutaneous melanoma, in De Vita VT Jr,Hellman S, Rosenberg SA (eds.): Cancer Principles and Practice of Oncology (ed 5) Philadelphia, PA, Lippincott-Raven, 1997; p. 1947–94.
2. Tilgen W. Malignant melanoma: Current therapeutic concepts. Oncologie 1995; 18: 534–47.
3. Luce JK, Thurman WG, Sega FM et al. Dacar5bazine-based chemotherapy for metastatic melanoma: Thirty year experience overview. J Exp Clin Cancer Res 2000; 19: 21–34.
4. Hill GJ, Moss SE, Golomb FM et al. DTIC and combination therapy for melanoma. Cancer 1981; 47: 2556–62.
5. Falkson G, Vam der Merwe AM, Falkson HC. Clinical experience with 5-(3,3-bis(2-chloro-ethyl)-1-triazeno)-imidazol-4-carboxamide (NSC 82196) in the treatment of metastatic malignant melanoma. Cancer Chemother Rep 1972; 56: 671–7.
6. Serrone L, Zeuli M, Sega FM et al. Dacarbazine-based chemotherapy for metastatic melanoma: Thirty year experience overview. J Exp Clin Cancer Res 2000; 19: 21–34.
7. Middleton MR, Lorigan P, Owen J et al. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 2000; 82: 1158–62.
8. Falkson CI, Ibrahim J, Kirkwood JM et al. Phase III trial of dacarbazine versus dacarbazine with interferon a-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 1998; 16: 1743–51.
9. Middleton MR, Grob J, Aaronson N et al. Final report of the French multicenter phase Ii study of the nitrosourea fotemustine in 153 evaluable patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158–66.
10. Jaquillat CI, Khayat D, Banzet P et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma. Cancer 1990; 66: 1873–8.
11. Jaquillat CI, Khayat D, Banzet P et al. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemother Pharmacol 1990; 25: 263–6.
12. Calabresi E, Aapro M, Becquart D et al. Multicenter phase Ii trial of the single agent fotemustine in patients with advanced malignant melanoma. Ann Oncol 1991; 2: 377–8.
13. Kleeberg UR, Engel Е, Israels P et al. Phase Ii trial of the single agent fotemustine in patients with metastatic melanoma (EORTC-MCG 18881). Jnkologie1991; 14: 81–3.
14. Schallreuter KU, Wenzel E, Brassow FW et al. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine. Cancer Chemother Pharmacol 1991; 29: 167–71.
15. Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Сlin Oncol 1999; 17: 2745–51.
16. Mornex F, Thomas L, Mohr P et al. A prospective randomized multicenter phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanota. Melanota Res 2003; 13: 97–103.
2. Tilgen W. Malignant melanoma: Current therapeutic concepts. Oncologie 1995; 18: 534–47.
3. Luce JK, Thurman WG, Sega FM et al. Dacar5bazine-based chemotherapy for metastatic melanoma: Thirty year experience overview. J Exp Clin Cancer Res 2000; 19: 21–34.
4. Hill GJ, Moss SE, Golomb FM et al. DTIC and combination therapy for melanoma. Cancer 1981; 47: 2556–62.
5. Falkson G, Vam der Merwe AM, Falkson HC. Clinical experience with 5-(3,3-bis(2-chloro-ethyl)-1-triazeno)-imidazol-4-carboxamide (NSC 82196) in the treatment of metastatic malignant melanoma. Cancer Chemother Rep 1972; 56: 671–7.
6. Serrone L, Zeuli M, Sega FM et al. Dacarbazine-based chemotherapy for metastatic melanoma: Thirty year experience overview. J Exp Clin Cancer Res 2000; 19: 21–34.
7. Middleton MR, Lorigan P, Owen J et al. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 2000; 82: 1158–62.
8. Falkson CI, Ibrahim J, Kirkwood JM et al. Phase III trial of dacarbazine versus dacarbazine with interferon a-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 1998; 16: 1743–51.
9. Middleton MR, Grob J, Aaronson N et al. Final report of the French multicenter phase Ii study of the nitrosourea fotemustine in 153 evaluable patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158–66.
10. Jaquillat CI, Khayat D, Banzet P et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma. Cancer 1990; 66: 1873–8.
11. Jaquillat CI, Khayat D, Banzet P et al. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemother Pharmacol 1990; 25: 263–6.
12. Calabresi E, Aapro M, Becquart D et al. Multicenter phase Ii trial of the single agent fotemustine in patients with advanced malignant melanoma. Ann Oncol 1991; 2: 377–8.
13. Kleeberg UR, Engel Е, Israels P et al. Phase Ii trial of the single agent fotemustine in patients with metastatic melanoma (EORTC-MCG 18881). Jnkologie1991; 14: 81–3.
14. Schallreuter KU, Wenzel E, Brassow FW et al. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine. Cancer Chemother Pharmacol 1991; 29: 167–71.
15. Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Сlin Oncol 1999; 17: 2745–51.
16. Mornex F, Thomas L, Mohr P et al. A prospective randomized multicenter phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanota. Melanota Res 2003; 13: 97–103.
Авторы
M.F. Avril, S. Aamdal, J.J. Grob et al (J Clin Oncol 2004; 22: 1118–25)
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.